Drug susceptibility profile of Mycobacterium tuberculosis isolated from HIV infected and uninfected pulmonary tuberculosis patients in Eastern India

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 3, 2010, Pages 195-201

  Chakraborty, Nilanjan ^a   De, Chandrav ^a   Bhattacharyya, Sohinee ^a   Mukherjee, Anirban ^a   Santra, Santanu ^b   Banerjee, Dipanjan ^b   Sarkar, Rathindra Nath ^c   Guha, Shubhashish Kamal ^c  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

Drug resistance; Extensively drug resistant tuberculosis; HIV; India; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PUBLIC HEALTH; RISK ASSESSMENT; SPUTUM ANALYSIS;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 76949088403     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2009.09.004     Document Type: Article

References (31)

1. WHO. Tuberculosis in the South-East Asia Region. The Regional Report: 2008. WHO Project No: SE ICP TUB. New Delhi: World Health Organization, Regional Office for South-East Asia; 2008, SEA-TB-302.
2. Becerra M.C., Bayona J., Freeman J., Farmer P.E., and Kim J.Y. Redefining MDR-TB transmission 'hot spots'. Int J Tuberc Lung Dis 4 (2000) 387-394
3. WHO. Drug Resistant Tuberculosis in the South-East Asia Region. Status Report. New Delhi: World Health Organization, Regional Office for South-East Asia; 2008.
4. Çiçek Saydam C., Çavuşoǧlu C., Burhanoǧlu D., Özkalay N., Badak F.Z., and Bilgiç A. Susceptibility of Mycobacterium tuberculosis strains to first-line and second-line antituberculosis drugs in Ege University Hospital. Turk J Med Sci. 31 (2001) 395-400
5. Mondal R., and Jain A. Extensively drug-resistant Mycobacterium tuberculosis, India. Emerg Infect Dis. 13 (2007) 1429
6. WHO. Anti-tuberculosis drug resistance in the world. Report 3. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva: World Heath Organization; 2004, WHO/HTM/TB/2004.343.
7. Balabanova Y., Ruddy M., Hubb J., Yates M., Malomanova N., Fedorin I., et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second line drug resistance and development of standardized therapy. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 136-139
8. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
9. Dye C., Hosseini M., and Watt C. Did we reach the 2005 targets for tuberculosis control?. Bull World Health Organ 85 (2007) 364-369
10. Singh S., Sankar M.M., and Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS 21 (2007) 2345-2347
11. Koenig R. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 319 (2008) 894-897
12. National AIDS Control Organization (NACO). Surveillance for HIV infections/AIDS cases in India (1986-1999). New Delhi: Ministry of Health and Family Welfare, Government of India; 2000.
13. NTI monograph series-1. Manual for establishment and functioning of a tuberculosis culture laboratory. Bangalore: National Tuberculosis Institute; 1983, p. 19.
14. Revised National Tuberculosis Control Programme (RNTCP). Guidelines for Quality Assurance of Smear Microscopy for Diagnosing Tuberculosis. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2005.
15. Chakraborty N., Bhattacharyya S., De C., Mukherjee A., Sarkar R.N., Banerjee D., et al. A rapid immunochromatographic assay for the detection of Mycobacterium tuberculosis antigens in pulmonary samples from HIV seropositive patients and its comparison with conventional methods. J Microbiol Methods 76 (2009) 12-17
16. Wayne L.G., and Kubica G.P. The mycobacteria. In: Sneath P.H.A., and Holt J.G. (Eds). Bergeys manual of systematic bacteriology Vol. 2 (1986), Williams & Wilkins Co, Baltimore 1435-1457
17. Niemann S., Richter E., and Gerdes S.R. Differentiation among members of the Mycobacterium tuberculosis complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of M. bovis. J Clin Microbiol 38 (2000) 152-157
18. Strong B.E., and Kubica G.P. Isolation and identification of Mycobacterium tuberculosis: a guide for the level II laboratory (1981), Centers for Disease Control, US Department of Health and Human Services, Atlanta, GA p. 118-126
19. Mukhopadhyay C., Garg A., and Ayyagari A. First documented cure of a suggestive exogenous reinfection in polymyositis with same but multidrug resistant M. tuberculosis. BMC Infect Dis 4 (2004) 63
20. WHO. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-Plus. Geneva: World Health Organization; 2001, WHO/CDS/TB/2001.288.
21. Khan I.S., Afzal O., and Rai M.A. XDR tuberculosis and the Indian-subcontinent: effective prevention strategies needed. Tuberculosis (Edinb) 89 (2009) 107-108
22. Udwadia Z.F., Jain S., Rodrigues C., and Mehta A. XDR tuberculosis in India: what's in a name?. Lancet Infect Dis 7 (2007) 441-442
23. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K.S., Wilson T., et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263 (1994) 172
24. Gordin F.M., Nelson E.T., Matts J.P., Cohn D.L., Erst J., Benator D., et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med. 154 (1996) 1478-1483
25. Pozniak A. The association between HIV and tuberculosis in industrialized countries. In: Davies P.D.O. (Ed). Clinical Tuberculosis. 3rd ed. (2003), Arnold, London 278-293
26. Migliori G.B., Ortmann J., Girardi E., Besozzi G., Lange C., Cirillo D.M., et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 13 (2007) 780
27. O'Brien R. Drug-resistant tuberculosis: etiology, management and prevention. Semin Respir Infect 9 (1994) 104-112
28. Narain R. Size and extent of tuberculosis problem in urban and rural India. Indian J Tuberc 9 (1962) 147-150
29. McGregor S. New TB strain could fuel South Africa AIDS toll. Reuters 11 September 2006. http://www.aegis.org/news/re/2006/RE060919.html [accessed 31 July 2009].
30. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis (2006), World Health Organization, Geneva
31. Hopewell P.C., Pai M., Maher D., Uplekar M., and Raviglione M.C. International standards for tuberculosis care. Lancet Infect Dis 6 (2006) 710-725